Pemigatinib, a small molecule inhibitor of FGFR1–3, has been approved in the US for treatment of unresectable cholangiocarcinoma with FGFR2 alterations, while erdafitinib, pan-FGFR inhibitor, is indicated for metastatic urothelial carcinoma with FGFR2 and FGFR3 alterations [56,57]. This evidence concerns the gene FGFR3 and cholangiocarcinoma.